

Special Issue on
Stereotactic Ablative Body Radiotherapy: New and Emerging Clinical Applications in an Evolving Practice Landscape

CALL FOR PAPERS

Radiation oncology is a technology driven field that thrives on new advances, bringing new and improved techniques to patients in their fight against cancer. The field was transformed 15-20 years ago with new reports of a technique called stereotactic body radiotherapy (SBRT), now referred to as stereotactic ablative body radiotherapy (SABR), which was being used for early stage non-small cell lung cancer in patients not fit for surgery. The results were impressive with high rates of local control and minimal toxicity in appropriately selected patients. As time progressed and more experience was generated with SABR, it was naturally utilized in a growing number of malignant and even benign conditions.

As oncologists that are part of a multidisciplinary team, SABR is not delivered in a vacuum and relies on the expertise of our surgical colleagues as well as coordination with medical oncology to determine appropriate sequencing of any additional therapy. In addition, we rely on radiologists to help with appropriate targeting as well as judging response to SABR. With this special issue of this journal which is listed in PubMed with a CiteScore of 3.53, we hope to attract submissions relating to new and exciting applications for SABR, updates or review articles on current standard indications for SABR, and thought provoking articles on combining SABR with other cancer therapies such as surgery and/or systemic therapy.

Potential topics include but are not limited to the following:

- ▶ Liver SABR (primary and metastatic)
- ▶ Prostate SABR
- ▶ Metastatic and nonprimary lung lesions managed with SABR
- ▶ Multiple site oligometastatic SABR
- ▶ Cardiac SABR
- ▶ Spine SABR
- ▶ SABR for benign lesions/conditions
- ▶ SABR in combination with systemic/targeted therapy
- ▶ New or unexpected reports of toxicity from SABR
- ▶ SABR as a boost after conventional radiation therapy
- ▶ Breast SABR as part of breast conservation
- ▶ SABR for recurrent head and neck cancer
- ▶ SABR in combination with targeted and/or systemic therapy
- ▶ SABR as an adjunct to surgery
- ▶ Imaging issues relating to SABR
- ▶ Clinical studies on interesting applications of SABR
- ▶ Safety and QA reports related to SABR
- ▶ Cost effectiveness analyses of SABR
- ▶ Brain SABR

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/jo/sabr/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Rodney E. Wegner, Allegheny Health Network Cancer Institute, Pittsburgh, USA

rodney.wegner@ahn.org

Guest Editors

John A. Vargo, West Virginia University Health Sciences Center, Morgantown, USA

jvargo@hsc.wvu.edu

Matthew Ward, Levine Cancer Institute, Charlotte, USA

matthew.ward@carolinashealthcare.org

Shaakir Hasan, Allegheny Health Network Cancer Institute, Pittsburgh, USA

shaakir.hasan@ahn.org

Submission Deadline

Friday, 21 September 2018

Publication Date

February 2019